Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8250)	1/8/1999 3:44:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Thanks, hope it works that way. Seems logical it would be easier to continue with XOMA. BTW the U.K. has updated its phls site. Data shows why extending the trial for a short period may be smart. PHLS data thru 52 week show 369 new reported cases from the 44 week total. 280 increase in lab confirmed cases. Also I have been told that as of last week there were 325 accrued patients in the trial, which may have been previously reported on this board. phls.co.uk